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Abstract: 
 
Phenobarbital-responsive DNA elements were identified in the 5’-flanking region of the 
chicken CYP2H1 gene by in reporter gene assays in a chicken hepatoma cell line (LMH). A 
264 bp enhancer sequence (PBRU) responded to phenobarbital and a variety phenobarbital-
type inducers. Analysis of putative transcription factor binding sites within the 264 bp 
element revealed a nuclear receptor half-site repeat (DR-4) neighboring a putative nuclear 
factor-1 site. This motif resembles phenobarbital response elements in the flanking regions of 
three phenobarbital-inducible genes, rat CYP2B2, mouse Cyp2b10 and human CYP2B6. 
Activation of the 264 bp element was eliminated after site-directed mutagenesis of the DR-4 
hexamer half-sites. 
 
Evidence for evolutionary conservation of this recognition site was indicated by activation in 
LMH cells of a mouse Cyp2b10 phenobarbital-responsive enhancer by the same spectrum of 
inducers that activate the CYP2H1 264 bp PBRU. Inhibition of this activation by okadaic 
acid may explain the reported inhibitory effects on induction of CYP2B1/2 and Cyp2b10 by 
this phosphatase inhibitor. We show this inhibition to occur directly on the 264 bp PBRU 
whereas the proximal promoter of CYP2H1 is induced by okadaic acid in reporter gene 
assays. These experiments exploit the unique phenobarbital-inducibility of the hepatoma-
derived cell line LMH. 
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Introduction: 
 
The cytochrome P-450 (CYP)1 gene superfamily encodes proteins responsible for the 
metabolism of numerous xenobiotic and endobiotic substrates (1). In addition, the 
transcription of drug-metabolizing enzymes from CYP1, CYP2 and CYP3 families can be 
induced a variety of compounds including substrates of these CYPs (2-7). Five different 
classes of prototypical inducer-drugs that activate distinct but overlapping classes of CYPs 
have been defined. For example, phenobarbital (PB) induces predominantly enzymes from 
the CYP2B, 2C and 3A subfamilies (2,5,7). These CYPs, as well as more than 50 other 
genes, are affected by PB and a number of structurally unrelated compounds classified as PB-
like inducers (8). PB-induction is observed in a wide variety of species ranging from Bacillus 
megaterium (9) to human. In vertebrates, drug-induction occurs predominantly in the liver 
and the intestine and to a lesser extent in other extrahepatic tissues such as skin, kidney, lung 
and brain (2,5). 
 
Phosphorylation and dephosphorylation events, cytokines and hormones affect enzyme 
induction by as yet unknown mechanisms (for review, see 10). Until recently, little was 
known about the molecular mechanisms of PB-type induction and a receptor for these drugs 
remains elusive. A major breakthrough has been the recent observation in several laboratories 
that orphan nuclear receptors are involved in CYP regulation (for review, see ref. 6,11,12). 
These findings emerged from the discovery and analysis of well defined PB-responsive 
elements in the flanking region of rat CYP2B2 and CYP3A1 (13-16), mouse Cyp2b10 
(17,18) and human CYP2B6 and CYP3A4 (19,20). In particular, the “pregnane X receptor” 
(PXR) is involved in the induction of CYP3As (21,22) and the “constitutive androstane 
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receptor” (CAR) mediates induction of CYP2Bs (19,23). There is considerable overlap 
between the PXR and the CAR systems in regard to inducers and genes affected. 
 
In chicken liver, CYP2H1 and CYP2H2 are major PB-inducible enzymes (24). The 5’-
flanking region of CYP2H1 has been analyzed by Hahn, Hansen and May and a 4.8 kb PB-
responsive enhancer fragment (-5898/-1057) was identified (25). Within this large DNA 
region, a small enhancer element of 240 bp was isolated (26). DNaseI footprinting, gel shift 
assays and mutational analysis of the 240 bp responsive element suggests that proteins 
binding to this element are different from the rodent Cyp2b10 responsive element and 
consequently, that induction mechanisms may be different in chicken and mammals (26). A 
limiting factor in these studies was that the 240 bp fragment mediated only a small response 
to PB in primary hepatocyte cultures when compared to activation of transcription in vivo 
(26). 
 
In the present study, we have analyzed the 5’-flanking region of CYP2H1 by reporter gene 
assays in the hepatoma cell line LMH that uniquely maintains a pleiotropic response to PB. 
We identified a 264 bp enhancer element which overlaps with the 240 bp element of Dogra et 
al. (26) and discovered a conserved nuclear receptor consensus sequence which mediates PB 
induction. This motif is also present in PB-inducible genes in mammals. Evolutionary 
conservation of this element was further supported by trans-species activation of a mouse 
Cyp2b10 PB-responsive enhancer module in LMH cells. Our results thus indicate that the 
proteins involved in the activation of the CYP2H1 264 bp PB-responsive element are 
identical or similar to proteins binding to the mouse and rat PB-responsive enhancer 
sequences. These findings document the experimental potential of the LMH-hepatoma cell 
line for PB-induction studies. 
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Materials and Methods: 
 
Reagents: Okadaic acid sodium salt and 1-nor-okadaone were purchased from Alexis 
Biochemicals, Läufelfingen, Switzerland. Dexamethasone, 2-methyl-1,2-di-3-pyridyl-1-
propanone (metyrapone), 5-pregnen-3-ol-20-one-16-carbonitrile (PCN) and rifampicin 
were obtained from Sigma, Buchs, Switzerland. Propylisopropylacetamide (PIA) was 
generously provided by Peter Sinclair, VA Hospital, White River Junction, Vt, USA. 
Glutethimide and -naphtoflavone were purchased from Aldrich, Buchs, Switzerland. 5-
Ethyl-5-phenyl-barbituric acid sodium salt (phenobarbital sodium salt) was obtained from 
Fluka, Buchs, Switzerland. All other reagents and supplies were obtained from standard 
sources. 
 
Culture and Transfection of LMH Cells. LMH cells were obtained from the American Type 
Culture Collection (ATCC No. 2117-CRL; Batch No.: F12213) and thawed immediately after 
arrival. They were cultivated in William’s E Medium supplemented with 10% fetal calf 
serum, 1% glutamine (2 mM) and 1% penicillin/streptomycin (50 IU/ml) on gelatin-coated 
dishes. Cells were seeded onto gelatin-coated plates at 70 - 80% surface density 24 hours 
prior to transfection. The cells were removed by trypsinization and transfections were 
performed using the FuGENE 6 Transfection Reagent (Boehringer Mannheim, Rotkreuz, 
Switzerland) in serum-free suspension according to the supplier’s manual. This procedure 
ensured equal transfection efficiencies for control and treated cells. The cells were then plated 
on 6-well dishes and medium was replaced 4 hours after transfection by induction or control 
medium, respectively.  
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Construction of Vectors: 5.9 kb of the CYP2H1 flanking region were analyzed as follows. An 
initial 4.8 kb fragment was kindly provided by Dr. Brian May, Dept. of Biochemistry, 
University of Adelaide, Adelaide, Australia. The fragment was cut with BamHI and inserted 
into BamHI-linearized pBLCAT5 vector generously provided by Dr. Günther Schütz, 
Institute of Cell and Tumor Biology, German Cancer Research Center, Heidelberg, Germany. 
The proximal 1.1 kb of the flanking region were amplified by PCR using the primers 5’ ACT 
GAG TTG TGT TTT GGG TCC 3’ and 5’ GGT GGG CAG AGG AAG AGA TGT 3’. The 
amplified product was then cut at the 5’ end with BamHI and ligated into a pBLCAT6 vector 
lacking the thymidine kinase-promoter. This vector was prepared by digestion with XhoI 
followed by Klenow fill-in and further digestion with BamHI to generate a 5’ BamHI – 3’ 
blunt-ended product. Both the 4.8 kb and the 1.1 kb fragment were sequenced by standard 
methods with an ABI Prism 310 Genetic Analyser (PE Applied Biosystems, Rotkreuz, 
Switzerland). The nucleotide sequence of the complete 5.9 kb 5’-flanking region of CYP2H1 
has been deposited in the GenBank nucleotide sequence data base2. 
 
Construction of subfragments. The subfragments of the 5.9 kb flanking region were obtained 
either by restriction digest or PCR-amplification (see Fig. 1A) and cloned into the pBLCAT5 
vector containing a tk-promoter. The 4.8 kb enhancer was cut with XbaI and BamHI to obtain 
fragments of 1376 bp and 3465 bp. Digestion of the 4.8 kb enhancer with AccI, XbaI and 
BamHI resulted in fragments of 1865 bp and 1599 bp. The 1599 bp fragment was further 
digested with AccI and StuI or BamHI and StuI to obtain 1016 bp or 583 bp fragments, 
respectively. The 331 bp fragment was produced by digesting the 583 bp fragment with 
BspMI and subsequent religation. The PB-responsive element from the 5’-flanking region of 
CYP2H1 was amplified with the primers 5’ CCC AAG CTT ACA CAA CAG GTG ATA 
AGG C 3’ and 5’ CGG GAT CCA TGG AAG GAC TCG AGA TAA G 3’ which contain 
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HindIII and BamHI sites, respectively, at their 5’ ends. The amplified fragment was 264 bp in 
length and was subsequently digested with BamHI and HincII resulting in the generation of a 
142 bp fragment. The vector was previously cut with AccI, blunt-ended with Klenow enzyme 
and further digested with BamHI. A 122 bp element was obtained by digesting the 264 bp 
fragment with HindIII and HincII. The vector was prepared by digestion with BamHI and 
ends were filled in with Klenow enzyme and followed by digestion with HindIII. 
The published 205 bp promoter fragment from CYP2H1 (27) was produced by PCR 
amplification using the primers 5’ CCC AAG CTT GGG ATG ATT ACC CAA AGT CA 3’ 
and 5’ CGC GGA TCC GCG CTG AAC TGG GAC CTG C 3’ containing HindIII and 
BamHI sites at their respective 5’ ends. The amplified PCR-product was subsequently 
cleaved with HindIII and BamHI and subcloned into pBLCAT6. All constructs were verified 
by sequencing. 
 
Site specific mutagenesis. Mutations in the putative nuclear receptor binding halfsites (Fig. 
5A) were introduced by PCR using standard overlap techniques. Briefly, subfragments were 
amplified with overlapping, mutated primers and vector primers. These subfragments were 
chosen as template in a second round of PCR using the vector primers alone for amplification 
of the full-length, mutated fragment. The vector primers in the first and the second round of 
PCR were 5’ TCA TGT CTG GAT CTC GAA GC 3’ and 5’ TTC GCC AAT GAC AAG 
ACG C 3’. The complete, mutated 264 bp fragments were then digested with BamHI and 
HindIII and cloned into the pBLCAT5 vector. The 5’ halfsite (AGTTCA) of the DR-4 
element was mutated with 5’ GGC CCC GCG GTC CTT GCC CTT CAG AGA CC 3’ and 
5’ GGA CCG CGG GGC CTT ATC ACC TGT TGT GTA 3’ exchanging the 6 bp of the 
halfsite with a SacII site. This mutation was denominated “HSc” and the mutation is depicted 
in bold letters in both of the primers and in Fig. 5A. The 3’ halfsite mutation (AGGGCA) was 
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obtained using the primers 5’ TCC TGA TAT CTT CAG AGA CCG AGC CAA TAC 3’ 
and 5’ AAG ATA TCA GGA AGT TCA GGC CTT ATC ACC 3’ where an EcoRV site 
replaced the hexamer halfsite. This mutation was called “RARc”. The double mutation was 
produced using the “HSc” mutation as template and the primer 5’ GGC CCC GCG GTC 
CTG ATA TCT TCA GAG ACC 3’ together with the second primer from the “RARc” 
mutant. This mutation was called “double” and contained SacII and EcoRV restriction 
endonuclease sites replacing the hexamer halfsites. Finally, mutating the 3’ halfsite 
(AGGGCA) into a canonical halfsite (AGTTCA) was achieved using the primers 5’ CTT 
CCT TGA ACT TTC AGA GAC CGA GCC AA 3’ and 5’ AAA GTT CAA GGA AGT 
TCA GGC CTT ATC ACC 3’. This mutation was denominated “perfect”. All constructs 
were verified by sequencing. 
 
Cloning of the mouse PBREM. The mouse 51 bp PBREM from Cyp2b10 and the 
corresponding 51 bp fragment from Cyp2b9 (28) were synthesized by Intron, Kaltbrunn, 
Switzerland with XbaI restriction sites at their ends to facilitate ligation into the pBLCAT5 
vector. For both the Cyp2b10 and the Cyp2b9 51 bp fragments, two copies were ligated head 
to tail into the reporter vector and these constructs were used in all experiments. All 
constructs were verified by sequencing. 
 
Analysis of Reporter Gene Expression. 16 hours after drug treatment, the cells were harvested 
and non-radioactive chloramphenicol acetyltransferase (CAT) assays were performed using 
the CAT-ELISA kit according to the manual of the supplier (Boehringer Mannheim, 
Rotkreuz, Switzerland). Cell extracts were also used for the determination of protein 
concentration using the ESL protein assay for normalization of specific CAT expression to 
total protein content (Boehringer Mannheim, Rotkreuz, Switzerland). 
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RNA Isolation and Taqman Analysis: RNA from LMH cells was isolated with the RNeasy 
Kit (Qiagen AG, Basel, Switzerland). One g total RNA was reverse-transcribed with the 
MMLV reverse transcriptase assay (Boehringer Mannheim, Rotkreuz, Switzerland). PCR was 
performed using the Taqman PCR Core Reagent Kit (PE Applied Biosystems, Rotkreuz, 
Switzerland) and the transcript level quantitated with an ABI PRISM 7700 Sequence 
Detection System (PE Applied Biosystems, Rotkreuz, Switzerland) according to the 
manufacturer’s protocol. Briefly, relative transcript levels in induced cells and non-treated 
control cells were determined using the relative quantitation method measuring the Ct. 
The following primers and fluorescent probes were used in these PCR reactions: CYP2H1: 
probe 5’ TCG CAG TTG CCT CCA GGT CTC CC 3’, forward primer 5’ AGG GTG GTG 
AGG GCA AAT C 3’, reverse primer 5’ ACA GGC ATT GTG ACC AGC AA 3’ and 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH): probe 5’ TGG CGT GCC CAT TGA 
TCA CAA GTT T 3’, forward primer 5’ GGT CAC GCT CCT GGA AGA TAG T 3’, 
reverse primer 5’ GGG CAC TGT CAA GGC TGA GA 3’. CYP2H1 and GAPDH transcript 
levels were measured in separate tubes and GAPDH was used for normalization of the 
CYP2H1 values. 
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Results: 
 
We sequenced 5.9 kb of 5’-flanking region and used this sequence for further isolation and 
analyses of PB-responsive elements (Fig. 1A). The subfragments derived from a previously 
reported 4.8 kb enhancer element (25) were inserted into the pBLCAT5 vector containing a 
heterologous tk-promoter. Inducibility was measured in transfected LMH cells after 16 hours 
of incubation with 400 M PB and compared to control values (Fig. 1B). The results revealed 
two major inducible regions, a 1376 bp fragment located at the 5’ end of the 5.9 kb flanking 
region (-5913/-4537) which was induced about 5 fold and a 264 bp fragment located at bp -
1657/-1393 mediating a 6 to 7 fold induction. We further dissected this 264 bp fragment and 
observed inducibility on the 5’ 122 bp piece (Fig. 1B). Since inducibility of this 122 bp 
fragment was only between 2 to 3 fold under the standard conditions, we used the 264 bp PB-
responsive element for subsequent analyses and called it PBRU (phenobarbital-response unit) 
according to the 163 bp PB-response unit in rat CYP2B2 (14). The identification of two 
response elements of 1376 bp and 264 bp in length from 5.9 kb of the chicken CYP2H1 5’-
flanking region allowed us compare the 264 bp PBRU to the described 51 bp PB-responsive 
enhancer module (PBREM) derived from mouse Cyp2b10 (28) in reporter gene assays. 
 
The 264 bp PBRU from chicken CYP2H1 was transfected into LMH cells and reporter gene 
assays were performed after applying different inducers for 16 hours. In parallel, the mouse 
51 bp PBREM from Cyp2b10 and its non-inducible mutated counterpart from Cyp2b9 (28) 
were transfected into LMH cells as a trans-species comparison. We used PB (400 M) and 
the prototypical PB-like inducers propylisopropylacetamide (PIA) (250 M) and glutethimide 
(500 M) all of which have predominant effects on CYP2B genes. Further, dexamethasone 
(50 M), and metyrapone (400 M), two common CYP3A inducers, and the prototypical 
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CYP1A1 inducer-naphtoflavone (10 M) were also tested. In addition, we were interested 
in the effects of 5-pregnen-3-ol-20-one-16-carbonitrile (PCN) (50 M) and rifampicin 
(100 M) due to their species-specific effects on CYP3As. The mouse PBREM from 
Cyp2b10 was inducible in the chicken LMH cell line whereas the analogous Cyp2b9 51 bp 
fragment was not inducible (Fig. 2). Those findings are in agreement with previous reports 
for mouse primary hepatocytes (18,28). Moreover, the spectrum of inducers activating the 
chicken 264 bp PB-responsive unit (PBRU) closely matched the pattern of the 51 bp 
Cyp2b10 PBREM (Fig. 2). The CYP2H1 PBRU was 12 fold induced by PB and whereas 22 
fold induction was observed by metyrapone and glutethimide. The Cyp2b10 PBREM 
conferred slightly higher induction levels, particularly 15 fold induction by PB, 21 fold 
induction by glutethimide and 30 fold induction by metyrapone. Dexamethasone and -
naphtoflavone exhibited only minor effects, generating about 4 fold induction of the 264 bp 
PBRU and between 5 and 7 fold induction of the 51 bp PBREM (Fig. 2). PCN and rifampicin 
activated neither the CYP2H1 PBRU nor the Cyp2b10 PBREM significantly (Fig. 2). None 
of the inducers significantly altered Cyp2b9 levels. These results show that the chicken 264 
bp PBRU and the mouse 51 bp PBREM react in the same way to different chemicals when 
transfected into LMH cells. Therefore, analysis of the sequence of the 264 bp PBRU and 
comparison to rodent and human PB-responsive element was attempted. 
 
The MatInspector program was used to analyze the 264 bp PBRU for putative regulatory 
elements and transcription factor binding sites using. It is accessible on the word wide web 
under http://genomatix.gsf.de/cgi-bin/matinspector/matinspector.pl. This algorithm scans DNA 
sequences for matches to nucleotide distribution matrices that define putative transcription 
factor binding sites accessible in the TRANSFAC database (29). Using a core similarity of 
0.75 and an optimized matrix similarity, a total of 45 matches were found. Those of potential 
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interest are depicted in Fig. 3: two putative activator protein-1 (AP-1) sites at –1539/-1533 
and –1440/-1434, two E-box family binding sites at –1445/-1433 and a putative nuclear 
factor-1 (NF-1) binding site at –1607/-1604. These findings are in agreement with previous 
reports by Dogra et al. (26) who assigned the site at –1607/-1604 to be a CCAAT box 
binding site, either for CCAAT/enhancer-binding protein (C/EBP) or for NF-1. Our analysis 
provided a number of additional recognition sites of potential importance for induction of 
CYPs. The two E-box family sites mentioned above were identified by MatInspector as sterol 
response element binding protein (SREBP) consensus elements. Two additional E-box family 
binding sites at the 5’ end of the 264 bp fragment (-1651/-1646) potentially bind upstream 
stimulating factor (USF), a basic-helix-loop-helix-leucine zipper DNA-binding protein (30). 
A C/EBP site (-1449/-1446) and a C/EBP homologous protein (CHOP) site (-1450/-1447) are 
clustered around the AP-1 and the SREBP sites, flanked by two hepatic nuclear factor-1 
(HNF-1) sites (-1489/-1482 and –1410/-1407) and a glucocorticoid receptor (GR)-consensus 
site (-1476/-1473). CHOP and C/EBP heterodimerize and trigger induction after stress 
stimuli such as nutrient deprivation, acute-phase response or toxin exposure (31) whereas 
HNF-1 is a member of the family of hepatic transcription regulatory proteins (32). SREBPs 
are involved in cholesterol homeostasis by inhibiting the de novo synthesis of cholesterol in a 
negative feedback signaling pathway (33). Mutational analysis of both SREBP sites alone 
and in combination showed no major effect on PB-induction of the 264 bp PBRU (data not 
shown). 
Since nuclear receptors have been demonstrated to be involved in PB-induction (6,11,12), we 
searched for hexamer halfsites (34) by defining patterns in the GCG sequence analysis 
program package and scanning the 264 bp fragment. Two canonical hexamer halfsites 
(AGT/GTCA) and one imperfect hexamer halfsite (AGTTGA) were identified at -1571/-1566, 
-1507/-1502 and -1535/-1530, respectively. None of these sites is in close proximity to each 
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other to form a repeat typical for nuclear receptor binding sites. However, two additional sites 
at –1637/-1632 and –1627/-1622 form a direct repeat with a spacing of four nucleotides (DR-
4) on the complementary strand (Fig. 3). The 5’ hexamer constitutes a canonical nuclear 
halfsite (AGTTCA) while the 3’ hexamer forms an imperfect halfsite (AGGGCA). 
This DR-4 element was found directly upstream of the putative NF-1 binding site forming a 
structure that is similar to the ones in rat CYP2B1/2, mouse Cyp2b10 and human CYP2B6 
PB-responsive elements (Fig. 4A). Sequence comparison of the PB-responsive fragments of 
CYP2H1, Cyp2b10 (28), CYP2B2 (13,14), CYP2B6 (19) and Cyp2b9 (28) revealed that the 
NR-1 site is conserved among the inducible CYPs. One mismatch is present in each halfsite 
in the CYP2H1 when compared to the rodent and human CYPs. A spacing of four 
nucleotides is common in chicken CYP2H1, rat CYP2B2, mouse Cyp2b10 and human 
CYP2B6 (Fig. 4B). On the 3’ side of the NF-1 binding site, no NR-2 like element is observed 
in the chicken CYP2H1 sequence as in the rodent and human response elements. Several 
putative transcription factor binding sites possibly involved in CYP regulation were identified 
on the 264 bp PBRU. Thereof, a hexamer repeat was chosen for further analysis in this report 
as this arrangement of binding sites is found in several PB-responsive elements of rodent and 
human CYPs. 
 
The significance of the DR-4 element found in the 264 bp PBRU from chicken CYP2H1 on 
PB-induction was tested by site-directed mutagenesis of the hexamer halfsites. Single knock-
outs of the 5’ hexamer half site (AGTTCA to CCGCGG, denominated “HSc”), the 3’ 
hexamer halfsite (AGGGCA to GGTATC, denominated “RARc”), the double knock-out of 
both halfsites (denominated “double”) and mutation of the more proximal halfsite into a 
canonical hexamer halfsite (AGGGCA to AGTTCA, denominated “perfect”) were performed 
by PCR (Fig. 5A). Mutagenized fragments were cloned into the pBLCAT5 reporter vector 
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and these constructs were transfected into LMH cells. Inducibility was measured after 
treating the cells for 16 hours with 400 M PB. Mutation of either halfsite alone or both 
together eliminated PB-induction of the 264 bp PBRU (Fig. 5B). When the more proximal 
halfsite was mutated into a canonical hexamer halfsite, 3 fold induction was observed but at a 
reduced level when compared to the 5 fold induction detected in the wildtype construct. 
These findings are similar to those reported for the Cyp2b10 PBREM in mouse primary 
hepatocytes (23). Thus, the DR-4 element found within the 264 bp PBRU plays a major role 
in mediating PB-induction of this enhancer element. 
 
Protein phosphorylation and dephosphorylation has a major effect on PB-induction (for 
review, see ref. 10 and for more recent reports, see ref. 35-37). Inhibition of protein 
phosphatases by okadaic acid (OA) has been linked to decreased PB-induction of rat 
CYP2B1/2 (38), mouse Cyp2b10 (39), Cyp2a5 and Cyp1A (37) as well as to an increase in 
mRNA of rat UDP-glucuronosyl transferase (UDPGT), another PB-inducible enzyme (40). 
Additionally, OA has been proposed to inhibit PB-triggered nuclear translocation of the 
orphan nuclear receptor mCAR1 in mouse liver in vivo (41). In our experiments, OA 
increased transcript levels of -aminolevulinate synthase (ALAS), the first and rate-limiting 
enzyme in heme synthesis, but inhibited induction of chicken CYP3A37 in LMH cells 
(unpublished observation). 
 
Induction of CYP2H1 was measured after 16 hours of exposure of LMH cells to 1 M OA or 
1 M 1-nor-okadaone either in the absence or presence of 400 M PB. The structural analog 
1-nor-okadaone of OA that does not inhibit protein phosphatases and was therefore used as 
negative control. Quantification of CYP2H1 mRNA was performed using the Taqman real-
time PCR quantification system as described in Materials and Methods. OA alone increased 
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CYP2H1 mRNA levels 15 fold whereas the negative analog 1-nor-okadaone had no effect 
(Fig. 6). The extent of induction by OA was in general lower than induction of CYP2H1 
mRNA by PB that triggered a 25 fold increase. When adding PB to OA-treated cells, no 
additive effect on transcript levels were observed and a 17 fold induction was obtained. 
 
Surprisingly, when testing the effect of OA with the 4.8 kb enhancer fragment of the 5’-
flanking region of CYP2H1 after 16 hours incubation, 1 M OA inhibited the 20 fold PB-
induction (Fig. 7A). In contrast, 1 M OA activated the more proximal 1.1 kb fragment (-
1057/-1) that contains the CYP2H1 promoter 8 fold after 16 hours of incubation. This 
fragment was not inducible by 400 M PB after 16 hours (Fig. 7A). To further localize the 
effects exerted by OA, we tested the 264 bp PBRU and the previously characterized CYP2H1 
promoter (-205/-1) in reporter gene assays (27). The promoter construct was 5 fold induced 
by OA comparable to the 8 fold induction of the 1.1 kb fragment after 16 hours treatment 
with 1 M OA. The 10 fold 264 bp PBRU induction by PB was abolished by 1 M OA after 
16 hours. Inhibition of dephosphorylation by OA blocks PB-induction of the 264 bp PBRU, 
which is in agreement with the hypothesis that OA blocks PB-triggered nuclear translocation 
of the orphan nuclear receptor CAR in mouse liver (41). OA further directly activates 
transcription from the CYP2H1 promoter presumably by inhibiting dephosphorylation of as 
yet unknown proteins. Nevertheless, our results show the similarity between the chicken 264 
bp PBRU and the rodent 51 bp PBREM in regard of regulation and modulation of PB-type 
induction mechanisms. 
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Discussion: 
 
In this report, we describe a 264 bp fragment in the 5’-flanking region of the chicken 
CYP2H1 gene that responds to phenobarbital. Sequence analysis of this fragment revealed a 
conserved nuclear receptor consensus sequence arranged as a direct hexamer repeat with 4 bp 
spacing, a so-called DR-4 element. Mutation of this DR-4 sequence eliminated PB-response 
under the chosen conditions. However, in experiments using serum-deprived medium, we 
observed some residual PB-induction on the mutated DR-4 constructs corresponding to about 
10% of PB-induction of the wildtype 264 bp PBRU indicating that other elements on the 264 
bp PBRU may also contribute to total PB-induction (unpublished observations). The DR-4 
element of the CYP2H1 gene described here resembles phenobarbital response units 
(PBRUs) or motifs (PBREMs) in the 5’-flanking region of rat CYP2B1 and CYP2B2 (13,14), 
mouse Cyp2b10 (18) and human CYP2B6 (19) indicating evolutionary conservation of this 
enhancer sequence. 
 
A mouse 51 bp PBREM from Cyp2b10 transfected into avian hepatoma cells responded in 
similar fashion to drugs and chemicals as the CYP2H1 PBRU. For example, PB and 
metyrapone strongly induced both the mouse 51 bp and the chicken 264 bp element whereas 
dexamethasone and -naphtoflavone had only weak effects on both response elements. The 
results with the 51 bp mouse PBREM in avian hepatoma cells closely resemble data from 
mouse hepatocyte primary cultures (28). High induction pattern similarity between the avian 
264 bp enhancer element and the mouse 51 bp PBREM in the chicken hepatoma cells suggest 
similar or identical transcription factors to be responsible for activation of these enhancers in 
chicken and mouse. 
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Different conclusions were reached by Dogra et al. who analyzed a 240 bp element (26) that 
overlaps with the 264 bp sequence reported here with exception of the most 5’ 17 bp and the 
most 3’ 7 bp. They interpreted their sequence analysis as revealing no common protein 
binding sites with the rodent enhancers and suggested that the proteins binding to the chicken 
enhancer must be different from those required for the activity of the PBRUs of mouse and 
rat CYP genes (26). One reason for this discrepancy may be the limited PB-inducibility of the 
240 bp fragment between 2 to 3 fold after 48 hours using 500 M PB in chicken primary 
hepatocytes (26). Moreover, employing a larger fragment of 556 bp containing the 240 bp 
enhancer resulted in 7 fold induction of CAT expression (26). In comparison to these results 
obtained in the primary hepatocyte cultures, inductions of the 264 bp PBRU in LMH cells 
were between 6 to 10 fold after 16 hours treatment with 400 M PB. It appears that either 
LMH cells are more responsive to PB-effects or that other factors such as easier transfection 
or higher cell homogeneity contribute to the discrepancy. Further, the additional bp of our 
fragment may have an enhancing effect on PB-inducibility compared to the shorter 240 bp 
fragment of Dogra and coworkers. 
 
We applied the MatInspector program that refers to the TRANSFAC database for identifying 
putative transcription factor binding sites (29). Of 45 recorded hits, we chose candidates 
likely to modify CYP regulation. A weak consensus sequence of the glucocorticoid receptor 
binding site at bp -2243/-2225 was observed to be essential for conferring maximal PB 
inducibility in the rat CYP2B1/2 163 bp PBRU (14). Further, glucocorticoid-responsive 
elements have been noted in other PB-responsive fragments in CYP2B genes at –1.4/-1.2 kb 
outside the PBRU or PBREM (reviewed in ref. 42). The arrangement of a DR-4 element 
upstream of a putative NF-1 site in the chicken CYP2H1 PBRU is repeated in the mouse 51 
bp PBREM and the rat CYP2B2 PBRU (14,23). The putative NF-1 binding in the chicken 
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PBRU is more distant from the NR-1 site and on the opposite strand compared to the rat and 
mouse elements. Moreover, the 5’ part of the bipartite NF-1 motif is not a canonical one in 
the chicken. Nevertheless, the chicken putative NF-1 site is more closely related to the NF-1 
consensus than the putative NF-1 site on the human CYP2B6 51 bp PBREM (see Fig. 4B) 
and comparison of the chicken sequence to the Transfac matrix for NF-1 reveals high 
conservation. Mutational analysis of the NF-1 site in vitro in reporter gene assays reduced 
PB-inducibility of the mouse 51 bp PBREM (23) whereas mutations of the NF-1 site of the 
rat PBRU in transgenic mice had no effect on inducibility (43). Therefore, the role of the NF-
1 site in PB-induction remains unclear. In the mouse 51 bp PBREM, the NR-1 site has been 
shown to be sufficient for mediating PB-induction (23). Therefore, the lack of a clear NR-2 
site in the chicken 264 bp PBRU may be of no consequence. A more in-depth analysis of the 
different putative binding sites is currently being attempted. 
 
Honkakoski et al. in a series of elegant experiments have demonstrated that the orphan 
nuclear receptor CAR forms heterodimers with the retinoid X receptor (RXR) and binds to 
the mouse Cyp2b10 51 bp PBREM in response to drug treatment (23). CAR was originally 
found to constitutively activate gene transcription in human (44) and mouse cells (45). A 
mechanism by which CAR mediates drug induction was recently proposed by Kawamoto et 
al. who postulated that CAR is located in the cytoplasm in the non-induced state and that PB 
or PB-like inducers lead to nuclear translocation with subsequent activation of CYPs (41). 
The protein phosphatase inhibitor OA could inhibit this nuclear translocation by unidentified 
mechanisms (41). 
 
Moreover, OA as well as several other protein phosphatase or protein kinase inhibitors have 
been shown to affect PB-induction in mouse, rat and chicken (for review, see ref. 10). 
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Induction of both rat CYP2B1/2 (38) and mouse Cyp2b10 mRNA (39) by PB was inhibited 
by OA whereas the chicken CYP2H1 transcript level was elevated after exposure to OA 
alone. Inhibition of protein phosphatases by OA leading to increased phosphorylation of 
different transcription factors such as C/EBP (46) and hyperphosphorylation of transcription 
factors or regulatory proteins have been associated with increased gene transcription (47). 
However, down-regulation of genes like the glucose-induced transcription of the S14 gene by 
OA has also been observed (48). Moreover, OA has been reported to increase the PB-
inducible phase II enzyme UDP-glucoronosyl transferase in rat (40). Thus OA exhibits a 
variety of gene-specific effects on transcription by influencing protein interaction with 
different regulatory elements. In this study, we show that OA predominantly activates 
transcription via the proximal promoter of CYP2H1 and blocks PB induction at the level of 
the PBRU. These findings explain why CYP2H1 mRNA is induced by OA to a certain level 
and that this OA-induction is not changed when adding PB. Our results may explain why in 
the rat OA inhibits CYP2B1/2 mRNA induction by PB but induces a CYP2B1/2 minigene 
containing the proximal sequence of the 5’-flanking region in reporter gene assays (39,49). 
The similarity of these data with the inhibition of the transfer of CAR to the nucleus in mouse 
liver suggests that a CAR-like receptor protein is involved in induction mediated by the 264 
bp PBRU in the CYP2H1 5’-flanking region of the chicken. 
 
In spite of its considerable activation by PB, it is suspected that the PBRU described here 
does not account for all of the transcriptional activation of the CYP2H1 gene expression in 
vivo. Additional elements, including the 1376 bp fragment in the more distal 5’-flanking 
region of CYP2H1, have been shown to be PB-inducible. Comprehensive analysis of this 
element is currently being carried out. Also, the induction of the 264 bp PBRU in reporter 
gene assays with different drugs does not fully explain the induction pattern of CYP2H1 
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mRNA. For example, 5-pregnen-3-ol-20-one-16-carbonitrile (PCN) exhibits only minor 
effects on the 264 bp PBRU, whereas the same drug markedly induced CYP2H1 gene 
expression in LMH cells (50). Receptor cross-talk and multiple response elements are 
observed in rodent and human PB-inducible CYP flanking regions. To date, the mouse 51 bp 
PBREM is the only well characterized PB-responsive element in the Cyp2b10 5’-flanking 
region and the rat CYP2Bs clearly contain more than one enhancer element (reviewed in ref. 
7,42). In another recent report, the flanking region of the human CYP3A4 was shown to 
contain at least three different hexamer halfsite repeats all contributing to the total response to 
rifampicin and PB (51), supporting the concept of multiple drug-response elements in these 
genes. On the basis of these observations, we hypothesize that a variety of different response 
elements and several nuclear receptors may be responsible for the overall response of 
CYP2H1 to PB and PB-type inducers. Candidate proteins include nuclear receptors such as 
CAR or PXR, the predominant regulator of CYP3A genes (21,22) since CYP2H1 induction 
was similar to the chicken CYP3A37 response after treatment with different drugs (50). 
 
We conclude from the present investigation that the chicken hepatoma cell line LMH is a 
valuable tool for the study of the regulatory mechanism of PB-type induction. LMH cells are 
the first PB-inducible cell line showing both qualitative and quantitative responses 
comparable to in vivo findings. They offer all of the advantages inherent to a continuously 
dividing cell line in the investigation of the transcription factors and response elements for 
drug-inducible genes. Therefore, our current investigations focus on identifying chicken 
nuclear receptors involved in PB-induction and the subsequent study of the interactions and 
redundancies of receptors and response elements mediating PB-response in LMH cells. 
Moreover, comparative mapping of homologous genes in different organisms surprisingly 
revealed that the organization of the human genome is closer to that of the chicken than to the 
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mouse (52). These findings and the results presented in this report suggest the chicken to be a 
potentially invaluable model system for comparison studies of molecular mechanisms of PB-
induction in chicken, rodents and humans. 
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Footnotes: 
 
1Abbreviations: AP-1, activator protein-1; bp, basepair(s); CAR, constitutive androstane 
receptor; CAT, chloramphenicol acetyl transferase; CEBP, CCAAT-enhancer binding 
protein; CHOP, C/EBP homologous protein; CYP, cytochrome(s) P-450; GRE, 
glucocorticoid response element; HNF-1, hepatic nuclear factor-1; kb, kilobase(s); LMH, 
leghorn male hepatoma; NF-1, nuclear factor-1; OA, okadaic acid; PB, phenobarbital; 
PBREM, phenobarbital-responsive enhancer module; PBRU, phenobarbital-responsive unit; 
PCN, 5-pregnen-3-ol-20-one-16-carbonitrile; PIA, propylisopropylacetamide; PXR, 
pregnane X receptor; RXR, retinoid X receptor; SREBP, sterol response element binding 
protein; tk, thymidine kinase; USF, upstream stimulatory factor 
 
2The nucleotide sequence for 5.9 kb of the 5’-flanking region of chicken CYP2H1 has been 
deposited in the GenBank database under GenBank Accession Number XXXX. 
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Figure Legends: 
 
Fig. 1. Analysis of the 5’-flanking region of CYP2H1. A, generation of subfragments of the 
4.8 kb enhancer fragment of the chicken CYP2H1 5’-flanking region by restriction 
fragmentation and PCR amplification as described in Materials and Methods. These 
fragments were cloned into the pBLCAT5 reporter vector containing a heterologous tk-
promoter. B, reporter gene assays of the fragments. The constructs were transfected into the 
chicken hepatoma cell line LMH in suspension before plating them on gelatin-coated 6-well 
dishes to ensure equal transfection efficiencies for control and treated cells. The cells were 
treated with 400 M phenobarbital for 16 hours, lysed and a CAT-ELISA was performed. 
The relative CAT expression was standardized against untreated control cells and expressed 
in fold induction. Data represent the average of three independent experiments with error bars 
representing standard deviations. 
 
Fig. 2. Trans-species comparison of the chicken CYP2H1 264 bp PB-response unit to the 
mouse Cyp2b10 51 bp PB-responsive enhancer module and the corresponding mouse 
Cyp2b9 51 bp fragment in LMH cells. The PB-responsive elements from the chicken 
CYP2H1 and the mouse Cyp2b10 and Cyp2b9 were cloned into the pBLCAT5 reporter 
vector containing a tk-promoter as described in Materials and Methods. The constructs were 
transfected into LMH cells in suspension and the cells were induced for 16 hours with PB 
(400 M), dexamethasone (50 M), metyrapone (400 M), -naphtoflavone (10 M), 
propylisopropylacetamide (PIA) (250 M), glutethimide (500 M), 5-pregnen-3-ol-20-one-
16-carbonitrile (PCN) (50 M) or rifampicin (100 M). Cells were harvested and a CAT-
ELISA was performed. The relative CAT expression was standardized against untreated 
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control cells and expressed in fold induction. Values represent the average of three 
independent experiments with error bars representing standard deviations. 
 
Fig. 3. Putative transcription factor binding sites on the 264 bp PB-response unit and on 
the CYP2H1 promoter. The 264 bp PBRU from the CYP2H1 5’-flanking region was 
analyzed using the MatInspector program for putative transcription factor binding sites 
defined in the TRANSFAC database. A core similarity threshold of 0.75 and an optimized 
matrix similarity were used in the MatInspector program (http://genomatix.gsf.de/cgi-
bin/matinspector/matinspector.pl). Hexamer halfsites were searched manually by looking for 
halfsite repeats found in known nuclear receptor binding sites. 
 
Fig. 4. Comparison of the structures of the chicken CYP2H1, the rat CYP2B2, the 
human CYP2B6 and the murine Cyp2b10 PB-responsive elements. A, structure and 
localization of the different PB-responsive elements from chicken CYP2H1, rat CYP2B1/2, 
human CYP2B6 and mouse Cyp2b10 on their respective PB-responsive elements. The 
hexamer halfsite repeats and the putative NF-1 binding sites reveal the conserved DR-4 / NF-
1 and NR-1 / NF-1 units, respectively. B, DNA sequence comparison of the chicken 
CYP2H1, the rat CYP2B2, the human CYP2B6, the mouse Cyp2b10 and the non-inducible 
mouse Cyp2b9 51 bp containing the hexamer halfsite / NF-1 units. The NR-1, the putative 
NF-1 and the NR-2 elements are boxed and nucleotides conserved in the four PB-inducible 
CYPs are highlighted in gray. 
 
Fig. 5. Site-directed mutagenesis of the DR-4 element within the 264 bp PB-response 
unit from CYP2H1. A, mutations of halfsites were introduced by site-directed mutagenesis 
using a PCR-based approach as described in Materials and Methods. Mutations are depicted 
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in bold. The constructs were subcloned into the pBLCAT5 vector containing a tk-promoter. 
B, LMH cells were transfected in suspension and treated with 400 M phenobarbital for 16 
hours. The cells were harvested and a CAT-ELISA was performed. The bars show relative 
induction values of expressed CAT protein standardized against non-treated control cells. 
Values are the average of three independent experiments and error bars represent standard 
deviations. 
 
Fig. 6. Inhibition of protein phosphatases by okadaic acid induces CYP2H1 mRNA. 
LMH cells were treated with 400 M PB and/or 1 M OA for 16 hours, total RNA was 
isolated and reverse transcribed. Relative mRNA levels of CYP2H1 from treated cells against 
control cells was determined with a Taqman ABI PRISM 7700 Sequence Detection System 
and normalized against GAPDH mRNA level as described in Materials and Methods. Values 
are the average of three independent experiments and the error bars represent standard 
deviations. 
 
Fig. 7. Localization of the okadaic acid effect on the 5’-flanking region of CYP2H1. A, 
LMH cells were transfected in suspension either with the pBLCAT5 vector containing a tk-
promoter and the 4.8 kb enhancer fragment from CYP2H1 or the pBLCAT6 vector lacking a 
heterologous promoter but containing the 1.1 kb proximal 5’-flanking region of CYP2H1. 
Cells were treated for 16 hours with 400 M PB and/or 1 M OA, harvested and a CAT-
ELISA was performed. The bars represent the relative induction of expressed CAT protein 
normalized to non-treated control cells. Values are the average of three independent 
experiments and the error bars represent standard deviations. B, the same protocol was 
followed as described in Fig. 7A but using the constructs of the 264 bp PB-responsive unit in 
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pBLCAT5 and the 205 bp promoter in pBLCAT6. Values are the average of three 
independent experiments and the error bars represent standard deviations. 
 







